Unraveling Ulcerogenesis: A Comprehensive Delve of Enteric & Nonenteric Ulcers

Year : 2024 | Volume :14 | Issue : 01 | Page : 25-40
By

Rishav Brijpuriya

Neelam Balekar

Ayushi Rai

  1. Student IPS Academy College of Pharmacy Madhya Pradesh India
  2. Professor IPS Academy College of Pharmacy Madhya Pradesh India
  3. Assistant Professor IPS Academy College of Pharmacy Madhya Pradesh India

Abstract

Enteric ulcers present a multifaceted landscape encompassing both peptic and non-peptic varieties, demanding a thorough exploration of their manifestations, causes, and pathophysiology. At the forefront of understanding lie pivotal factors such as Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs usage, lifestyle choices, and stress, each wielding significant influence over ulcer development and progression. The intricate interplay of these factors underscores the complexity of enteric ulcer etiology. Helicobacter pylori infection—a prevalent culprit—inflicts chronic gastritis and mucosal damage, fostering an environment ripe for ulcer formation. Stress, recognized as a potent modulator of gastrointestinal function, amplifies susceptibility to ulceration via mechanisms involving altered gastric acid secretion and mucosal blood flow. Diagnosis of enteric ulcers demands astute clinical acumen and judicious employment of diagnostic modalities such as endoscopy, biopsy, and non-invasive testing for Helicobacter pylori. Prompt identification and treatment are paramount, emphasizing the critical role of healthcare professionals in orchestrating tailored intervention plans. Treatment strategies encompass a multifaceted approach targeting causative factors and symptom relief. Helicobacter pylori eradication regimens, coupled with acid-suppressing medications and cytoprotective agents, form the cornerstone of pharmacotherapy. Lifestyle modifications, including dietary adjustments and stress management techniques, complement pharmacological interventions to optimize therapeutic outcomes. A holistic understanding of enteric ulcers empowers healthcare professionals to navigate the intricacies of diagnosis and treatment, thereby fostering positive outcomes and enhancing the quality of life for individuals grappling with this debilitating condition. By embracing a comprehensive paradigm encompassing etiology, diagnosis, and management, clinicians stand poised to alleviate suffering and promote wellness in patients afflicted with enteric ulcers

Keywords: ulcers, gastroesophageal reflux disease, inflammatory bowel diseases, nonsteroidal anti-inflammatory drugs, Helicobacter pylori

[This article belongs to Research & Reviews: A Journal of Medicine(rrjom)]

How to cite this article: Rishav Brijpuriya, Neelam Balekar, Ayushi Rai. Unraveling Ulcerogenesis: A Comprehensive Delve of Enteric & Nonenteric Ulcers. Research & Reviews: A Journal of Medicine. 2024; 14(01):25-40.
How to cite this URL: Rishav Brijpuriya, Neelam Balekar, Ayushi Rai. Unraveling Ulcerogenesis: A Comprehensive Delve of Enteric & Nonenteric Ulcers. Research & Reviews: A Journal of Medicine. 2024; 14(01):25-40. Available from: https://journals.stmjournals.com/rrjom/article=2024/view=143598


References

  1. Tian M, Dong J, Wang Z, Lu S, Geng F. The effects and mechanism of Kangfuxin on improving healing quality and preventing recurrence of gastric ulcer. Biomedicine & Pharmacotherapy. 2021; 138:
  2. Mustafa M, Menon J, Muiandy RK, Fredie R, Sein MM, Fariz A. Risk factors, diagnosis, and management of peptic ulcer disease. J Dent Med Sci. 2015; 14(7): 40–46p.
  3. Shim YK, Kim N. Nonsteroidal anti-inflammatory drug and aspirin-induced peptic ulcer disease. The Korean Journal of G 2016; 67(6): 300–312p.
  4. Tsongo L, Nakavuma J, Mugasa C, Kamalha E. Helicobacter pylori among patients with symptoms of gastroduodenal ulcer disease in rural Uganda. Infection Ecology & E 2015; 5(1): 26785.
  5. Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nature Clinical Practice Gastroenterology & Hepatology. 2006; 3(2): 80–89p.
  6. Ammar AS, Khalid AU, Noumani AR. A case report of duodenal and enteric perforation in a single patient. European Journal of Medical Case Reports. 2020; 4(8): 263–265p.
  7. Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. Risk factors for the presence of symptoms in peptic ulcer disease. Clinical E 2017; 50(6): 578–584p.
  8. Weng A, Su X, Yang C, Zheng B, Zheng L, Jian C, Fang J. Telephone follow-up by clinical pharmacists can improve treatment outcomes in patients with peptic ulcers: a prospective randomized study. Medicine. 2022; 101: 42p.
  9. Feliciano O, Gutierrez O, Valdés L, Fragoso T, Calderin AM, Valdes AE, Llanes R. Prevalence of Helicobacter pylori vacA, cagA, and iceA genotypes in Cuban patients with upper gastrointestinal diseases. BioMed Research I 2015; 2015: 753710.
  10. Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, Engstrand L, Vieth M, Stolte M, Talley NJ, Agréus L. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. American Journal of E 2006; 163(11): 1025–1034p.
  11. Saeed M, Bass S, Chaisson NF. Which ICU patients need stress ulcer prophylaxis? Cleveland Clinic Journal of Medicine. 2022; 89(7): 363–367p.
  12. Xia B, Xia HH, Ma CW, Wong KW, Fung FM, Hui CK, Chan CK, Chan AO, Lai KC, Yuen MF, Wong BC. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician‐referred uninvestigated dyspeptic patients in Hong Kong. Alimentary Pharmacology & T 2005; 22(3): 243–249p.
  13. Holle GE. Pathophysiology and modern treatment of ulcer disease. International Journal of Molecular M 2010; 25(4): 483–491p.
  14. Tarris G, de Rougemont A, Charkaoui M, Michiels C, Martin L, Belliot G. Enteric viruses and inflammatory bowel disease. Viruses. 2021; 13(1): 104p.
  15. Jeon HJ, Lee JS, Lee BS, Kim SH, Lee ES, Sung JK, Moon HS, Kang SH, Lee HS, Choi S, Sa-Kong H. Typhoid fever presenting with gastric ulcer bleeding. BMC G 2022; 22(1): 116p.
  16. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011; 62(6): 591–599p.
  17. Sonnenberg A. Historic changes of Helicobacter pylori‐associated diseases. Alimentary Pharmacology & T 2013; 38(4): 329–342p.
  18. Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. The American Journal of M 2019; 132(4): 447–456p.
  19. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009; 136(6): 1863–1873p.
  20. Gurusamy KS, Pallari E. Medical versus surgical treatment for refractory or recurrent peptic ulcer. Cochrane Database of Systematic Reviews. 2016; 2016(3): CD011523.
  21. Kim BW. Diagnosis and treatment of peptic ulcer disease: present and future perspective. The Korean Journal of Gastroenterology. 2016; 67(6): 318–320p.
  22. Savarino V, Marabotto E, Zentilin P, Savarino E. The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. Expert Review of Clinical P 2019; 12(11): 1011–1012p.
  23. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004; 127(2): 395–402p.
  24. Chen Y, Liu Q, Hu F, Ma J. Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases. MicrobiologyO 2020; 9(11): e1120.
  25. Vrettos I, Voukelatou P, Katsoras A, Theotoka D, Kalliakmanis A. Diseases linked to polypharmacy in elderly patients. Current Gerontology and Geriatrics R 2017; 2017: 4276047.
  26. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 NIH patients and comparison with 2229 cases from the literature. Medicine. 2006; 85(6): 295p.
  27. Osumi H, Fujisaki J, Suganuma T, Horiuchi Y, Omae M, Yoshio T, et al. A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication. PloS O 2017; 12(8): e0183980.
  28. Rockey DC, Koch J, Cello JP, Sanders LL, McQuaid K. Relative Frequency of Upper Gastrointestinal and Colonic Lesions in Patients with Positive Fecal Occult-Blood Tests. N Engl J Med. 1998; 339(3): 153–159p.
  29. Laine L, Jensen DM. Management of patients with ulcer bleeding. Official Journal of the American College of Gastroenterology. 2012; 107(3): 345–360p.
  30. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004; 329(7464): 480p.
  31. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. The Journal of Clinical I 2003; 111(12): 1805–1812p.
  32. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Journal of H 2009; 145(1): 24-33p.
  33. Lanas A, Chan FK. Peptic ulcer disease. The Lancet. 2017; 390(10094): 613–624p.
  34. Tarris G, de Rougemont A, Charkaoui M, Michiels C, Martin L, Belliot G. Enteric viruses and inflammatory bowel disease. Viruses. 2021; 13(1): 104p.
  35. Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, et al. Clinical guidelines for drug-related peptic ulcer. Gut and L 2020; 14(6): 707p.
  36. Feliciano O, Gutierrez O, Valdés L, Fragoso T, Calderin AM, Valdes AE, et al. Prevalence of Helicobacter pylori vacA, cagA, and iceA genotypes in Cuban patients with upper gastrointestinal diseases. BioMed Research I 2015; 2015: 753710.
  37. Lee DP, Chang KJ. Endoscopic management of GERD. Digestive diseases and sciences. 2022; 67(5): 1455–1468p.

Regular Issue Subscription Original Research
Volume 14
Issue 01
Received January 29, 2024
Accepted February 2, 2024
Published April 18, 2024